Karyopharm Therapeutics Inc. quarterly report, Q2 FY2016

Karyopharm Therapeutics Inc. — Q2 2016 Form 10-Q

Reporting period: Three and six months ended June 30, 2016. Unaudited consolidated financial statements; amounts below are in U.S. dollars unless stated otherwise.

Business context

Karyopharm is a clinical-stage biotechnology company developing SINE compounds that inhibit XPO1. Its lead candidate, selinexor, was being studied in hematologic cancers and solid tumors. The company had no approved drugs and had generated no revenue from drug sales; substantially all activity and spending supported research and development.

Financial results and liquidity

At June 30, 2016, cash and cash equivalents were $37.717m; short- and long-term investments were $127.952m; and restricted cash was $0.483m, totaling $166.2m. This compares with $210.1m in those categories at year-end 2015. Total assets were $170.897m, current assets $124.200m, current liabilities $15.523m, and total liabilities $17.331m. No borrowings are reported on the balance sheet; liabilities consisted primarily of accounts payable, accruals and deferred rent. The filing gives no meaningful operating margin because revenue was immaterial relative to expenses.

First-half investing activities provided $22.968m, mainly reflecting investment maturities exceeding purchases; financing activities provided $0.436m, primarily from option exercises and employee stock purchases. Cash and cash equivalents fell $20.641m to $37.717m. Stock-based compensation expense was $11.563m for the first half, versus $8.231m a year earlier.

Changes versus prior comparable periods

Q2 net loss narrowed by $2.537m year over year, while first-half net loss narrowed by $1.545m. First-half R&D decreased $1.383m, despite higher personnel and stock-compensation costs, primarily as clinical-trial, preclinical toxicology and consulting costs declined. First-half G&A was nearly unchanged. Operating cash use declined $4.265m year over year. Revenue remained immaterial and fell $0.091m in both the quarter and first half.

Outlook, commentary and risks

• Management expected existing cash, cash equivalents and investments to fund its operating plan and capital needs into the middle of 2018, and expected to end 2016 with more than $120m in cash, cash equivalents, restricted cash and investments. The company also said it would need substantial additional funding; no committed external funding source was identified.
• Management expected R&D and G&A expenses to remain consistent for the rest of 2016, while describing significant expenses and increasing operating losses as likely for the foreseeable future.
• As of the filing, expected selinexor data milestones were STORM topline data in September 2016; SOPRA interim analysis in late 2016 and topline data in mid-2017; SADAL topline data in early 2017; and SEAL Phase 2 topline data in mid-2017. These were expectations, not reported outcomes.
• Key risks include clinical-trial failure or delay, regulatory uncertainty, patient enrollment and safety, reliance on third-party manufacturers and research organizations, competition, intellectual-property challenges, and the need to raise additional capital. The filing noted potential selinexor adverse events including gastrointestinal symptoms and fatigue; more severe thrombocytopenia and neutropenia; and increased sepsis rates in AML patients receiving high doses.
• The company reported no material change in contractual obligations and no off-balance-sheet arrangements. It stated disclosure controls and procedures were effective at the reasonable-assurance level and reported no material quarterly change in internal control over financial reporting.
• Market risks include interest-rate sensitivity and foreign-currency exposure on certain overseas contracts; the company did not hedge currency risk. Management said an immediate 10% interest-rate change would not materially affect investment fair value.

Important facts for investors to verify

• Whether clinical milestones occurred on schedule and whether trial results support regulatory submissions, particularly the expected STORM data.
• Whether actual cash burn and spending remain consistent with the mid-2018 runway estimate and the projected year-end 2016 liquidity.
• Future financing needs, available terms and potential dilution, including use of the $50m at-the-market offering; no additional shares under that agreement had been sold by July 31, 2016.
• Clinical safety and efficacy findings, regulatory feedback, manufacturing readiness and any changes to commercialization plans.
• Potential stock dilution: 5.421m options and 0.479m unvested RSUs were outstanding at June 30, 2016; basic and diluted loss per share excluded anti-dilutive securities.